Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CASC's Cash to Debt is ranked higher than
100% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. CASC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CASC' s Cash to Debt Range Over the Past 10 Years
Min: 5.92  Med: 170.56 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CASC's Interest Coverage is ranked higher than
100% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CASC' s Interest Coverage Range Over the Past 10 Years
Min: 976.29  Med: 9999.50 Max: 9999.99
Current: No Debt
976.29
9999.99
F-Score: 4
Z-Score: -5.40
M-Score: -1.62
WACC vs ROIC
20.04%
-133.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -41.53
CASC's ROE (%) is ranked lower than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. CASC: -41.53 )
Ranked among companies with meaningful ROE (%) only.
CASC' s ROE (%) Range Over the Past 10 Years
Min: -163.15  Med: -64.90 Max: 43.53
Current: -41.53
-163.15
43.53
ROA (%) -36.52
CASC's ROA (%) is ranked lower than
59% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. CASC: -36.52 )
Ranked among companies with meaningful ROA (%) only.
CASC' s ROA (%) Range Over the Past 10 Years
Min: -80.5  Med: -50.43 Max: 23.29
Current: -36.52
-80.5
23.29
ROC (Joel Greenblatt) (%) -2045.38
CASC's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CASC: -2045.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CASC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3364.41  Med: -2040.51 Max: 635.37
Current: -2045.38
-3364.41
635.37
EBITDA Growth (3Y)(%) 92.10
CASC's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CASC: 92.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CASC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60  Med: -8.30 Max: 92.1
Current: 92.1
-60
92.1
EPS Growth (3Y)(%) 74.00
CASC's EPS Growth (3Y)(%) is ranked higher than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. CASC: 74.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CASC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.1  Med: -8.50 Max: 74
Current: 74
-56.1
74
» CASC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:MSTX, NAS:ADVM, NAS:OHRP, NAS:GTXI, OTCPK:PRTX, OTCPK:ARUXF, OTCPK:OPBXF, NAS:ADMA, NAS:ABEO, NAS:AUPH, NAS:CORI, AMEX:OCX, NAS:XENE, NAS:PPHM, NAS:CFRX, NAS:VBLT, AMEX:NAVB, OTCPK:DFFN, NAS:MIRN, AMEX:ATNM » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.

Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.

Ratios

vs
industry
vs
history
Current Ratio 8.83
CASC's Current Ratio is ranked higher than
73% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CASC: 8.83 )
Ranked among companies with meaningful Current Ratio only.
CASC' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 11.89 Max: 36.71
Current: 8.83
1.67
36.71
Quick Ratio 8.83
CASC's Quick Ratio is ranked higher than
74% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CASC: 8.83 )
Ranked among companies with meaningful Quick Ratio only.
CASC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 11.89 Max: 36.71
Current: 8.83
0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.60
CASC's Price/Net Cash is ranked higher than
76% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. CASC: 2.60 )
Ranked among companies with meaningful Price/Net Cash only.
CASC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.04  Med: 5.43 Max: 38.63
Current: 2.6
1.04
38.63
Price/Net Current Asset Value 2.46
CASC's Price/Net Current Asset Value is ranked higher than
78% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. CASC: 2.46 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CASC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.91  Med: 5.18 Max: 38
Current: 2.46
0.91
38
Price/Tangible Book 2.33
CASC's Price/Tangible Book is ranked higher than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. CASC: 2.33 )
Ranked among companies with meaningful Price/Tangible Book only.
CASC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 4.64 Max: 73.64
Current: 2.33
0.84
73.64

More Statistics

EPS (TTM) $ -0.40
Beta2.44
Short Percentage of Float9.67%
52-Week Range $0.82 - 4.02
Shares Outstanding (Mil)94.96

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.41 -0.43 -0.43
EPS w/o NRI ($) -0.41 -0.43 -0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CASC

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2016
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 28 2016
Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of... Jun 28 2016
Cascadian Therapeutics (CASC) Jumps: Stock Rises 10.4% Jun 24 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 23 2016
Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016
Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016
Biotech Stock Mailbag: Cascadian Therapeutics, Global Blood Therapeutics, Bad Favus Jun 20 2016
CASCADIAN THERAPEUTICS, INC. Financials Jun 16 2016
Cascadian Therapeutics (Nasdaq: CASC) to Ring The Nasdaq Stock Market Closing Bell Jun 14 2016
Cascadian Therapeutics (Nasdaq: CASC) to Ring The Nasdaq Stock Market Closing Bell Jun 14 2016
Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and Outlines Key Development... Jun 14 2016
CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 14 2016
Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and Outlines Key Development... Jun 14 2016
Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 Jun 10 2016
ONCOTHYREON INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Jun 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)